ARIAD Investor Slams $5.2B Takeda Deal For Unfair Process
An ARIAD Pharmaceuticals shareholder launched a putative class action in Massachusetts federal court on Saturday over the hedge fund-backed oncology biotech's planned $5.2 billion sale to Japan's Takeda, alleging that the...To view the full article, register now.
Already a subscriber? Click here to view full article